255 related articles for article (PubMed ID: 35625739)
1. Exploring the Utility of NK Cells in COVID-19.
Deng X; Terunuma H; Nieda M
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625739
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
Front Immunol; 2022; 13():888248. PubMed ID: 35844604
[TBL] [Abstract][Full Text] [Related]
3. NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients.
Dizaji Asl K; Mazloumi Z; Majidi G; Kalarestaghi H; Sabetkam S; Rafat A
Cell Biochem Funct; 2022 Aug; 40(6):559-568. PubMed ID: 35833321
[TBL] [Abstract][Full Text] [Related]
4. Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19.
Maruthamuthu S; Rajalingam K; Kaur N; Morvan MG; Soto J; Lee N; Kong D; Hu Z; Reyes K; Ng D; Butte AJ; Chiu C; Rajalingam R
Front Genet; 2022; 13():845474. PubMed ID: 35273641
[No Abstract] [Full Text] [Related]
5. Natural killer cell exhaustion in SARS-CoV-2 infection.
Gallardo-Zapata J; Maldonado-Bernal C
Innate Immun; 2022 Aug; 28(6):189-198. PubMed ID: 35733383
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
7. NK cells in COVID-19-from disease to vaccination.
Hammer Q; Cuapio A; Bister J; Björkström NK; Ljunggren HG
J Leukoc Biol; 2023 Oct; 114(5):507-512. PubMed ID: 36976012
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Memory NK Cell to Protect Against COVID-19.
Soleimanian S; Yaghobi R
Front Pharmacol; 2020; 11():1309. PubMed ID: 32973527
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
Front Immunol; 2021; 12():652223. PubMed ID: 34367128
[TBL] [Abstract][Full Text] [Related]
10. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
11. Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.
Jeyaraman M; Muthu S; Bapat A; Jain R; Sushmitha ES; Gulati A; Channaiah Anudeep T; Dilip SJ; Jha NK; Kumar D; Kesari KK; Ojha S; Dholpuria S; Gupta G; Dureja H; Chellappan DK; Singh SK; Dua K; Jha SK
Heliyon; 2021 Jul; 7(7):e07635. PubMed ID: 34312598
[TBL] [Abstract][Full Text] [Related]
12. Early expansion of activated adaptive but also exhausted NK cells during acute severe SARS-CoV-2 infection.
Claus M; Pieris N; Urlaub D; Bröde P; Schaaf B; Durak D; Renken F; Watzl C
Front Cell Infect Microbiol; 2023; 13():1266790. PubMed ID: 37712059
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of natural killer cells in COVID-19.
Lee MJ; Blish CA
Nat Immunol; 2023 Oct; 24(10):1628-1638. PubMed ID: 37460639
[TBL] [Abstract][Full Text] [Related]
14. CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells.
Ma M; Badeti S; Chen CH; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
bioRxiv; 2021 Jan; ():. PubMed ID: 33469580
[TBL] [Abstract][Full Text] [Related]
15. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
Front Immunol; 2021; 12():763460. PubMed ID: 35003077
[TBL] [Abstract][Full Text] [Related]
17. NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade.
Lee G; Schauner R; Burke J; Borocz J; Vasana S; Sobieraj L; Giraudo M; Jackson Z; Ansari Q; Navas M; Sakr H; Wald D
Front Immunol; 2023; 14():1022890. PubMed ID: 37483595
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 immunotherapy: a mathematical model.
Tavares JN; Gomes E
Math Med Biol; 2023 Jun; 40(2):199-221. PubMed ID: 37038322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
